AMEX · Biotechnology

OS Therapies Incorporated (OSTX) Stock

$1.56 +2.63% AMEX: OSTX Healthcare

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Valuation

MetricValue
Price$1.56
Market Cap$69.48M
P/E Ratio-1.42
P/B Ratio-5.43
P/S Ratio0.00
EPS (TTM)$-0.30
52-Week High$2.57
52-Week Low$1.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE483.33%
ROA-483.25%
ROCE350.90%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.12
Current Ratio54.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-5.0M$-4.0M$-4.0M$-7.0M$-29.0M
Net Profit$-7.0M$-6.0M$-8.0M$-9.0M$-29.0M
EPS$-0.33$-0.28$-0.39$-0.52$-0.98
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$1.0M$1.0M$6.0M$7.0M
Total Liabilities$12.0M$18.0M$25.0M$5.0M$13.0M
Cash$0$0$0$6.0M$0
Borrowings$7.0M$10.0M$15.0M$0$0

Latest News

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program TMX Newsfile · Jul 8, 2026 OS Therapies Third Quarter 2026 Corporate Outlook TMX Newsfile · Jul 6, 2026 OS Therapies Appoints Dr. Craig Eagle to Board of Directors TMX Newsfile · Jul 2, 2026 OS Therapies Provides U.S. Regulatory Update TMX Newsfile · Jun 30, 2026 OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma TMX Newsfile · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-4.0M$-3.0M$-7.0M$-14.2B
Investing Cash Flow$0$0$0$0$-467.0M
Financing Cash Flow$0$0$0$31.0M$9.4B
Net Cash Flow$-1.0M$0$0$5.0M$-5.3B
Free Cash Flow$-4.0M$-4.0M$-3.0M$-7.0M$-14.2B

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-1.98
FCF Yield-20493.83%
Quick Ratio0.00
Interest Coverage-449.59
Return 1Y-0.63%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAGAdagene Inc. $3.67 +1.66% -7.78 $138.17M 0.00%
COEPCoeptis Therapeutics Holdings, Inc. $10.99 -8.57% -4.45 $38.62M 0.00%
CRVO $2.56 -3.76% -1.09 $23.70M 0.00%
EQ $2.57 +3.21% -5.28 $91.29M 0.00%
HOWL $0.40 -3.04% -0.33 $19.54M 0.00%

About OS Therapies Incorporated

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

OS Therapies Incorporated is led by CEO Paul A. Romness, employs 4 people, headquartered in US, publicly traded since 2024.

OS Therapies Incorporated (OSTX) stock trades at $1.56 with a market capitalization of $69.48M. The stock is valued at a price-to-earnings (P/E) ratio of -1.42, price-to-book of -5.43, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.15 and $2.57, and currently trades 39.3% below its 52-week high.

On profitability, OS Therapies Incorporated generates a return on equity (ROE) of 483.33% — well above the market average, a sign of a high-quality business, return on capital employed of 350.90%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: ostherapies.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides